In the present review, the implications of oxidative stress and Nrf2 activation in the therapy of neurodegeneration are revised, with a particular focus on Alzheimer’s disease (AD) and Parkinson’s disease (PD), which are the two most prevalent age-related neurodegenerative diseases [1]. The gene discussed is NFE2L2; the disease is Parkinson disease.